Protalix Biotherapeutics, Inc. PLX 深 滬
等待開盤 11-05 09:30:00 美东时间
2.69
+0.080
+3.07%
華盛通- 最 高2.73
- 今 開2.61
- 成交量 87.08万股
- 最 低 2.58
- 昨 收 2.61
- 總市值 2.17亿
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 1.08%
- 52周最低 1.65
- 委 比 -29.74%
- 總股本 8057.16万
- 歷史最高 77.00
- 量 比 2.04
- 振 幅 5.75%
- 歷史最低 0.70
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protalix BioTherapeutics Inc收跌1.16%，成交额186.92万美元
11月3日，Protalix BioTherapeutics Inc（PLX）收跌1.16%，报2.56美元，成交额186.92万美元，市值2.06亿美元。 行...
11-03 07:37
Protalix BioTherapeutics Inc收跌2.75%，成交额103.66万美元
10月27日，Protalix BioTherapeutics Inc（PLX）收跌2.75%，报2.48美元，成交额103.66万美元，市值2亿美元。 行情数...
10-27 06:41
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference
CARMIEL, Israel, Oct. 26, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commerc...
10-26 18:50
Protalix BioTherapeutics Inc收跌2.96%，成交额315.11万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:42
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
09-09 22:47
普罗塔利斯生物制药 (PLX) 2026年第二季度业绩电话会议：Elfabrio驱动营收增长
受Elfabrio推动增长，Protalix BioTherapeutics 2026年第二季度营收增长26.8%至1990万美元，同时管理层重申了其全年业绩展望。
08-14 08:35
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which beat the analyst consensus estimate of $12.931 million by 53.86 percent. This is a 2...
08-12 18:51
Protalix BioTherapeutics Q2 Earnings Preview
Protalix BioTherapeutics (PLX) is scheduled to announce Q2 earnings results on Wednesday, August 12th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $...
08-11 23:10
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q1 2026 Management View “During the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfab...
05-13 23:52
